Try our Advanced Search for more refined results

Merck Answers USPTO In Singulair Patent Re-Exam

By Leigh Kamping-Carder (November 10, 2009, 3:56 PM EST) -- Merck & Co. has responded to an early finding from the U.S. Patent and Trademark Office that its patent covering blockbuster asthma and allergy drug Singulair is invalid, although it may be too late to affect the pharmaceutical giant's ongoing feud with generics maker Teva Pharmaceutical Industries Ltd....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!